Impact of Triacetin- and Tributyrin-Based Formulations on IBS Microbiome Composition and SCFA Profiles: A Preclinical Study
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27198910 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Liam Jenkins Sánchez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium. Hauptthemen laut MEDLINE: Triglycerides, Fatty Acids, Volatile, Triacetin, Irritable Bowel Syndrome. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Irritable bowel syndrome (IBS) is a prevalent yet poorly understood functional gut disorder frequently associated with microbial dysbiosis, making microbiome-targeting interventions a promising management strategy. In this study, we evaluated the microbiome-modulating potential of three doses of triacetin (TA; ReBiome™; 100, 200 and 300 mg/day) and two finished formulations containing TA and/or tributyrin (TB): Active Biome™ (AB) and Bio Complete 3™ (BC3). Inulin served as a benchmark prebiotic. The validated ex vivo Systemic Intestinal Fermentation Research (SIFR®) technology pipeline was applied using fecal microbiota from eight adults with IBS. TA dose-dependently increased short-chain fatty acid (SCFA) levels from 100 mg/day, significantly increasing acetate and butyrate while maintaining low gas formation. In addition to acetate and butyrate, AB and BC3 also promoted propionate while BC3 induced a particularly pronounced butyrate increase. Overall, both formulations induced stronger SCFA but milder gas increases than inulin. TA, AB and BC3 enriched IBS-depleted, butyrate-associated OTUs related to Faecalibacterium and Anaerobutyricum species. AB and BC3 increased microbial diversity (community modulation score (CMS)) by promoting Bifidobacteriaceae, Lachnospiraceae and Bacteroidaceae. Overall, TA and TA/TB-containing formulations promoted butyrate production, potentially helping mitigate IBS symptom severity by inducing a favorable fermentation profile with limited gas formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.
- Gundry MD®, 145 S. Fairfax Avenue, Suite 200, Los Angeles, CA 90036, USA.
ORCID-Profile: Liam Jenkins Sánchez, Aurélien Baudot, Pieter Van den Abbeele
Zitieren
APA
Jenkins Sánchez, L., Poppe, J., Baudot, A., Vu, L. D., Villella, W., & Van den Abbeele, P. (2026). Impact of Triacetin- and Tributyrin-Based Formulations on IBS Microbiome Composition and SCFA Profiles: A Preclinical Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27198910
Vancouver
Jenkins Sánchez L, Poppe J, Baudot A, Vu LD, Villella W, Van den Abbeele P. Impact of Triacetin- and Tributyrin-Based Formulations on IBS Microbiome Composition and SCFA Profiles: A Preclinical Study. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27198910
BibTeX
@article{JenkinsSnchez2026,
author = {Jenkins Sánchez, Liam and Poppe, Jonas and Baudot, Aurélien and Vu, Lam Dai and Villella, Will and Van den Abbeele, Pieter},
title = {Impact of Triacetin- and Tributyrin-Based Formulations on IBS Microbiome Composition and SCFA Profiles: A Preclinical Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27198910}
}
EUVIMED